Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polymeric biosurfactants

一种生物表面、活性剂的技术，应用在人工合成的聚合材料有效成分、药物组合、药物输送等方向，能够解决没有胶原刺激活性等问题

Inactive Publication Date: 2009-12-09
THERAPEUTIC PEPTIDES
View PDF26 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to US Patent 6,974,799, the Val-Trp dipeptide has no significant collagen stimulating activity and its combination with the Gly-Gln-Pro-Arg tetrapeptide does not show any enhancement of this property relative to the level achieved with the tetrapeptide alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0159] The following examples further illustrate the invention. The components and specific ingredients are provided in typical form and various modifications are possible within the scope of the invention in light of the foregoing disclosure. Percentages are by weight of the total composition unless otherwise indicated.

[0160] Example 1 - Gel

Embodiment 2

[0161] Example 2 - Cream / Lotion

Embodiment 3

[0162] Example 3 - Nanoparticle Concentrate

Phase A

DI water 70-90%

Phase B

medium chain triglycerides (C 6 -C 12 ) 2-8%

Lecithin 2-8%

Medium chain fatty acids (C 6 -C 12 ) 2-8%

Lysine or Arginine 1-2%

Polymerized acylated biosurfactant SEQ ID NO 21* 10-1000ppm

*Acquired from Therapeutic Peptides Inc. (Harahan, LA)

Mix Phase B into Phase A with a high speed homogenizer at 10,000-12,000 rpm for about 10 minutes at 30-40°C. The resulting mixture is then processed into a colloid mill at over about 10,000 psi, producing a particle size of less than about 200 nm. The resulting concentrate is added to a conventional bust cream at a concentration of about 1% to about 20%.

[0163] Example 4 - Improvement of signs of aging

[0164] The efficacy of a topical composition containing a therapeutically effective amount of a polymeric acylated biosurfactant of the present invention in reducing signs of aging can be tested as follows: reduction in severity of supe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to biosurfactants that can self-assemble or auto- aggregate into polymeric micellar structures and their use in topically-applied dermatologic products. The invention relates in particular to polymeric acylated biosurfactants (PABs) conforming to the formula Acyl-AA-Term where Acyl is an 8- to 22-membered carbon chain, branched or unbranched, saturated or unsaturated, AA is a consecutive sequence of four to nine amino acid residues, where at least one, preferably at least two of the amino acid residues is charged, and Term is an acid C-terminus or an amide C-terminus. PABs of the present invention have low critical micelle concentrations (predominantly less than about 100 ppm) in an aqueous environment of Minimal Essential Media (MEM) and can lower the surface tension in the aqueous MEM environment to less about 50 dynes / cm2. They also have the ability to increase metabolic soluble proteins.

Description

[0001] Cross References to Related Applications [0001] This application claims priority to US Provisional Application Serial No. 60 / 809,825, filed June 1, 2006. Statement of Federally Funded Research [0002] Not applicable. field of invention [0003] The present invention relates to biosurfactants capable of self-assembling or auto-aggregating into polymeric micellar structures and their use in topical dermatological products. In particular, the present invention relates to polymeric acylated biosurfactants having a low critical micelle concentration (from about 1.0 ppm to about 200 ppm) in minimal essential medium and having an increased ability to metabolize soluble proteins. Additionally, they have rather low toxicity, preferably, LD in 37-year-old female fibroblasts 50 Greater than 200ppm, and the ability to increase extracellular skin matrix protein synthesis and / or increase cell turnover rate. Background of the invention [0004] Surfactants are well known as ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/74B01F3/00B01F17/00A61K38/08B01F23/00C09K23/00
CPCA61K47/488C07K7/06C07K5/1008C07K5/101A61K47/48238A61K38/08C07K5/1019A61K47/62A61K47/6907A61P17/00A61P17/16A61P31/00A61P31/04Y02A50/30A61K31/74A61K38/16A61K9/127
Inventor D·欧文L·范
Owner THERAPEUTIC PEPTIDES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com